Antimuscarinic Agents as Substances of Abuse: A Review

  title={Antimuscarinic Agents as Substances of Abuse: A Review},
  author={S. Dilsaver},
  journal={Journal of Clinical Psychopharmacology},
  • S. Dilsaver
  • Published 1988
  • Psychology, Medicine
  • Journal of Clinical Psychopharmacology
Centrally active antimuscarinic agents are generally used in psychiatry to treat the extrapyramidal side effects of antipsychotic medications. However, these agents may have antidepressant and mood-elevating properties, and the literature suggests they are liable to abuse. The author reviews this literature and discusses its implication. 
Preliminary note: dangerous use of anticholinergic drugs in Brazil.
To better evaluate the non-medical use of anticholinergic substances in Brazil, a review of the local literature was performed and it was found that the percentage of youngsters indulging in such use was higher than the percentage found for cocaine, barbiturates, cough syrups and amphetamine-related drugs. Expand
Olanzapine Dependence
Olanzapine is the second-generation antipsychotic most frequently prescribed for treatment of schizophrenia and bipolar affective disorder. Its side effects include sedation, weight gain,Expand
Abuse OF Olanzapine by Substance Abusers
  • R. Reeves
  • Psychology, Medicine
  • Journal of psychoactive drugs
  • 2007
The case reported here involves a 25-year-old male who abused olanzapine, both by itself and in combination with other drugs, which has sedative properties for some patients, especially in large doses. Expand
Anticholinergic Drug Abuse and Misuse
SummaryAbuse of the centrally acting anticholinergic agents is a phenomenon occasionally reported in the medical literature. Anticholinergics, most often used in psychiatry to treatExpand
Management of Acute Antipsychotic-Induced Extrapyramidal Syndromes
While the incidence of EPS is reduced with the newer ‘atypical’ antipsychotics, such as clozapine and risperidone, EPS is not eliminated and, at present, effective use of antipsychotic drugs continues to require proficiency in the management of these troublesome adverse effects. Expand
Pharmacological treatment of substance-abusing schizophrenic patients.
  • S. Siris
  • Psychology, Medicine
  • Schizophrenia bulletin
  • 1990
The author discusses the role of neuroleptic medications in treating the psychotic diathesis, preventing recurrences of schizophrenic symptomatology, counteracting psychotic exacerbations engendered by abused substances, and potentially generating side effects such as akinesia and akathisia that patients may attempt to "self-medicate" with substances of abuse. Expand
Amitriptyline Dependence and Its Associations: A Case Report and Literature Review
Amitriptyline has long been suspected for abusive potential based on a few case reports, and reports add evidence in favor of the hypothesis, and the probable mechanisms by which patients turn to abusing and be addicted to the drug are discussed. Expand
Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology
  • S. Dilsaver
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica
  • 1988
The capacity of MAOI to exert amphetamine‐like effects presynaptically, and the propensity of somatic treatments for depression to subsensitize presynaptic receptors regulating the release of catecholamines, can provide a basis for the development of psychotic syndromes upon the withdrawal ofMAOIs. Expand
Antipsychotic withdrawal phenomena in the medical-surgical setting.
The temporal relationship of these prodromal symptoms to reduction in the dosage or discontinuation of neuroleptics distinguishes them from the effects of abrupt withdrawal. Expand
Adjunctive Medication in the Maintenance Treatment of Schizophrenia and its Conceptual Implications
Beyond the continuing use of neuroleptic medication, psychopharmacological treatment approaches during the maintenance phase of schizophrenia often involve adjunctive medication. Appropriate use ofExpand